- Conditions
- Hypertensive Disorder
- Interventions
- Blood pressure cuff
- Device
- Lead sponsor
- University of South Carolina
- Other
- Eligibility
- 18 Years to 54 Years · Female only
- Enrollment
- 421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Columbia, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 961–984
of 12,606
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Volunteers
- Interventions
- M518101, M518101 Vehicle, Sodium lauryl sulfate, Saline
- Drug · Other
- Lead sponsor
- Maruho North America Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Fair Lawn, New Jersey
- Conditions
- COPD
- Interventions
- indacaterol, placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 6
- States / cities
- Fullerton, California • Saint Charles, Missouri • Charlotte, North Carolina + 3 more
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- Not listed
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Overweight and Obesity, Academic Acheivement
- Interventions
- Healthy Summer Learners, 21st Century Summer Learning Center
- Behavioral
- Lead sponsor
- University of South Carolina
- Other
- Eligibility
- 6 Years to 9 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Columbia, South Carolina
- Conditions
- Peripheral Arterial Disease, Intermittent Claudication, Peripheral Vascular Disease
- Interventions
- Magnetic Resonance Angiography
- Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2018
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Mild Hepatic Encephalopathy
- Interventions
- AST-120
- Drug
- Lead sponsor
- Ocera Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 29 more
- Conditions
- Asymptomatic Amyloid-positive
- Interventions
- Atabecestat, 5 mg, Atabecestat, 25 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 557 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
- Conditions
- Transient Insomnia
- Interventions
- Ramelteon, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 289 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2003
- U.S. locations
- 12
- States / cities
- Palm Springs, California • San Diego, California • Miami, Florida + 9 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Control Food, Fiber Fortified Food
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Primary Hyperaldosteronism
- Interventions
- Baxdrostat, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 15
- States / cities
- San Francisco, California • Farmington, Connecticut • Springfield, Illinois + 11 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Dexmethylphenidate, Mixed Amphetamine Salts, ER, placebo
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Northbrook, Illinois
- Conditions
- Alcohol Use Disorder, Posttraumatic Stress Disorder
- Interventions
- Mobile Mindfulness-Relapse Prevention (mMBRP), Exercise/healthy eating mobile app
- Behavioral
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Menlo Park, California • San Francisco, California
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- 3,4-Methylenedioxymethamphetamine (MDMA), Placebo, Massed Prolonged Exposure (PE)
- Drug · Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Kidney Stones, Nephrolithiasis
- Interventions
- ureteroscopy, CVAC
- Device
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Major Depressive Disorder
- Interventions
- SEP-363856, Placebo
- Drug · Other
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 929 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more
- Conditions
- Alzheimer's Disease
- Interventions
- CPC-201
- Drug
- Lead sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
- Industry
- Eligibility
- 50 Years to 79 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- West Palm Beach, Florida
- Conditions
- Alzheimer's Disease
- Interventions
- Albutein 5%, Control
- Biological · Other
- Lead sponsor
- Instituto Grifols, S.A.
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Whiting, New Jersey
- Conditions
- Meningococcal Disease
- Interventions
- serogroup B meningococcal vaccine
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 11 Years to 18 Years
- Enrollment
- 203 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 8
- States / cities
- Encinitas, California • Atlanta, Georgia • St Louis, Missouri + 5 more
- Conditions
- Aging, Weight Loss, Treatment Adherence
- Interventions
- Dial Health Research Study
- Other
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 25 Years to 45 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Baton Rouge, Louisiana
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Tranexamic Acid (IV), Placebo
- Drug
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 45 Years and older · Male only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- PreDiabetes
- Interventions
- Early TRE, Mid-day TRE, Control Schedule
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Opioid Use Disorder
- Interventions
- Brenipatide, Placebo, Buprenorphine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 35 more
- Conditions
- High Risk Pregnancy, Congenital Heart Disease, Fetal Hydrops, Twin Monochorionic Monoamniotic Placenta, Gastroschisis, Fetal Demise, Stillbirth, Fetal Arrhythmia, Long QT Syndrome, Intrauterine Fetal Death, Sudden Infant Death, Pregnancy Loss, Twin Twin Transfusion Syndrome, Birth Defect, Fetal Cardiac Anomaly, Fetal Cardiac Disorder, Fetal Death, Brugada Syndrome, Fetal Tachycardia
- Interventions
- Fetal Magnetocardiogram and Neonatal Electrocardiogram, Substudy only: Maternal/Infant Pharmacogenomic assessment postnatally
- Diagnostic Test · Genetic
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 2
- States / cities
- Madison, Wisconsin • Milwaukee, Wisconsin